Abstract
Improved 4-week complete remission rate by additional use of daunorubicin in the medium term of induction chemotherapy in adult Ph-negative acute lymphoblastic leukemia with high proportion of blasts
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
